Charles L Bisgaier
Overview
Explore the profile of Charles L Bisgaier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srivastava R, Cornicelli J, Markham B, Bisgaier C
Front Pharmacol
. 2018 Jun;
9:471.
PMID: 29867478
Our clinical studies have demonstrated that gemcabene, a small molecule in late-stage clinical development, lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP). This observation was further confirmed in a cell-based study...
2.
Oniciu D, Hashiguchi T, Shibazaki Y, Bisgaier C
PLoS One
. 2018 May;
13(5):e0194568.
PMID: 29847555
Background And Aims: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) can advance, if untreated, to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and liver-related death. In the United...
3.
Srivastava R, Cornicelli J, Markham B, Bisgaier C
Mol Cell Biochem
. 2018 Apr;
449(1-2):167-183.
PMID: 29644527
Inflammation plays a key role in setting the stage leading to atherosclerosis progression, and high-sensitivity C-reactive protein (CRP) has been recognized as a predictor of cardiovascular risk. As a monotherapy...
4.
Bisgaier C, Oniciu D, Srivastava R
J Cardiovasc Pharmacol
. 2018 Apr;
72(1):3-10.
PMID: 29621036
Gemcabene, a late-stage clinical candidate, has shown efficacy for LDL-C, non-HDL cholesterol, apoB, triglycerides, and hsCRP reduction, all risk factors for cardiovascular disease. In rodents, gemcabene showed changes in targets,...
5.
Bisgaier C, Ackermann R, Rea T, Rodrigueza W, Hartman D
Pharmacol Res
. 2016 May;
111:86-99.
PMID: 27155060
Epidemiological studies support an inverse correlation between HDL-C and cardiovascular disease. However, low HDL-C levels do not always segregate with premature disease. These include, LCAT deficiency and the apolipoproteinA-IMilano (AIM)...
6.
Rodrigueza W, Woolliscroft M, Ebrahim A, Forgey R, McGovren P, Endert G, et al.
Cancer Chemother Pharmacol
. 2014 May;
74(1):151-66.
PMID: 24832107
PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to a region upstream of the BCL-2 gene. Exposure of tumor cells to PNT100 results in suppression of...
7.
Tolcher A, Rodrigueza W, Rasco D, Patnaik A, Papadopoulos K, Amaya A, et al.
Cancer Chemother Pharmacol
. 2013 Dec;
73(2):363-71.
PMID: 24297683
Purpose: Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-base DNA oligonucleotide called PNT100. Methods: Patients...
8.
Parolini C, Marchesi M, Lorenzon P, Castano M, Balconi E, Miragoli L, et al.
J Am Coll Cardiol
. 2008 Mar;
51(11):1098-103.
PMID: 18342229
Objectives: This study sought to evaluate in vivo the minimal dose of apolipoprotein (apo) A-I(Milano) phospholipid complex (recombinant apoA-I(Milano) and 1-palmitoyl-2-oleoyl phosphatidylcholine complexes [ETC-216]) able to induce atherosclerosis regression in...
9.
Marchesi M, Booth E, Rossoni G, Garcia R, Hill K, Sirtori C, et al.
Atherosclerosis
. 2007 Oct;
197(2):572-8.
PMID: 17945238
Irreversible myocardial injury is a potential consequence of coronary artery revascularization. Reperfusion leads to the production of oxidized products that can damage myocardium. High-density lipoproteins (HDL) are effective at removing...
10.
Srivastava R, Jahagirdar R, Azhar S, Sharma S, Bisgaier C
Mol Cell Biochem
. 2006 Feb;
285(1-2):35-50.
PMID: 16477380
Fenofibrate, a selective (1)PPAR-alpha activator, is prescribed to treat human dyslipidemia. The aim of this study was to delineate the mechanism of fenofibrate-mediated reductions in adiposity, improvements in insulin sensitivity,...